CO2019008876A2 - Liposomas hiperestabilizados aumentan el ataque direccionado a células mitóticas - Google Patents

Liposomas hiperestabilizados aumentan el ataque direccionado a células mitóticas

Info

Publication number
CO2019008876A2
CO2019008876A2 CONC2019/0008876A CO2019008876A CO2019008876A2 CO 2019008876 A2 CO2019008876 A2 CO 2019008876A2 CO 2019008876 A CO2019008876 A CO 2019008876A CO 2019008876 A2 CO2019008876 A2 CO 2019008876A2
Authority
CO
Colombia
Prior art keywords
hyperstabilized
mitotic cells
targeted attack
liposomes increase
increase targeted
Prior art date
Application number
CONC2019/0008876A
Other languages
English (en)
Inventor
Chang Zhi Adrian Ng
Shen-Yi Ian Cheong
Original Assignee
Temasek Life Sciences Laboratory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temasek Life Sciences Laboratory Ltd filed Critical Temasek Life Sciences Laboratory Ltd
Publication of CO2019008876A2 publication Critical patent/CO2019008876A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se relaciona con el campo del tratamiento del cáncer. Más específicamente, la invención se refiere a liposomas hiperestables útiles para el tratamiento del cáncer y a métodos para tratar un cáncer usando liposomas hiperestables.
CONC2019/0008876A 2017-01-18 2019-08-15 Liposomas hiperestabilizados aumentan el ataque direccionado a células mitóticas CO2019008876A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762447498P 2017-01-18 2017-01-18
PCT/SG2018/050026 WO2018136002A1 (en) 2017-01-18 2018-01-17 Hyperstabilized liposomes increase targeting of mitotic cells

Publications (1)

Publication Number Publication Date
CO2019008876A2 true CO2019008876A2 (es) 2020-01-17

Family

ID=62909275

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0008876A CO2019008876A2 (es) 2017-01-18 2019-08-15 Liposomas hiperestabilizados aumentan el ataque direccionado a células mitóticas

Country Status (18)

Country Link
US (1) US11331272B2 (es)
EP (1) EP3570818B1 (es)
JP (2) JP7232530B2 (es)
KR (1) KR20190122676A (es)
CN (1) CN110381922A (es)
AU (1) AU2018210748B2 (es)
BR (1) BR112019014718A2 (es)
CA (1) CA3050686A1 (es)
CL (1) CL2019002002A1 (es)
CO (1) CO2019008876A2 (es)
IL (1) IL268099B2 (es)
MA (1) MA47319A (es)
MX (1) MX2019008533A (es)
PH (1) PH12019501650A1 (es)
RU (1) RU2765736C2 (es)
SG (2) SG11201906539YA (es)
TW (1) TWI816656B (es)
WO (1) WO2018136002A1 (es)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0768117B2 (ja) * 1983-05-06 1995-07-26 ベスター・インコーポレイテツド 薬剤放出調整用小胞製剤
CA1338702C (en) 1987-03-05 1996-11-12 Lawrence D. Mayer High drug:lipid formulations of liposomal- antineoplastic agents
US5714163A (en) * 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US6120800A (en) * 1997-09-25 2000-09-19 Nexstar Pharmaceuticals, Inc. Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting properties
EP1429726A2 (en) 2001-09-06 2004-06-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem A method for preparing liposome formulations with a predefined release profile
EP1746976B1 (en) 2004-05-03 2017-01-11 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery
JP5057362B2 (ja) 2004-11-02 2012-10-24 国立大学法人 東京医科歯科大学 リポソーム及びこれを用いた細胞に対する物質注入方法
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
US20110033461A1 (en) * 2008-03-12 2011-02-10 Vladimir Ratushny Combination Therapy for the Treatment of Cancer
US20090285881A1 (en) * 2008-04-16 2009-11-19 Abbott Laboratories Cationic lipids and uses thereof
US8318817B2 (en) * 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US20120058178A1 (en) 2009-03-30 2012-03-08 Eisai R&D Management Co., Ltd. Liposome Composition
ES2568778T3 (es) 2009-04-17 2016-05-04 3M Innovative Properties Company Lámina de protección contra rayos con conductor estampado
US9220682B2 (en) * 2009-04-22 2015-12-29 Emory University Nanocarrier therapy for treating invasive tumors
WO2010143972A2 (en) 2009-06-08 2010-12-16 Epitarget As Acoustically sensitive drug delivery particles comprising non-lamellar forming lipids
US20120301537A1 (en) * 2011-05-23 2012-11-29 Delta-Fly Pharma, Inc. LIPOSOME CONTAINING shRNA MOLECULE TARGETING A THYMIDYLATE SYNTHASE AND USE THEREOF
EP2773426B1 (en) * 2011-10-31 2018-08-22 Mallinckrodt LLC Combinational liposome compositions for cancer therapy
DK2950784T3 (da) * 2013-02-01 2021-07-05 Zoneone Pharma Inc Fjernladning af svagt vandopløselige lægemidler i liposomer
WO2014160337A1 (en) * 2013-03-13 2014-10-02 Mallinckrodt Llc Liposomal cisplatin compositions for cancer therapy
KR101925507B1 (ko) 2013-03-15 2018-12-05 타이완 리포솜 캄퍼니 리미티드 조절 약물 방출 리포솜 조성물
CN106659683A (zh) * 2014-01-14 2017-05-10 约翰斯·霍普金斯大学 包封修饰的环糊精复合物的脂质体组合物及其应用
EP3131587A4 (en) * 2014-04-14 2017-11-01 Endocyte, Inc. Drug delivery conjugates for treating resistant cancer and for use in combination therapy
US20160175250A1 (en) * 2014-12-23 2016-06-23 Tolmar Inc. Method for Making Liposomes Containing an Active Pharmaceutical Ingredient
JP2018505224A (ja) 2015-02-13 2018-02-22 オーピーナノ シーオー エルティーディーＯＰ Ｎａｎｏ Ｃｏ．，Ｌｔｄ． ナノ粒子を含む組成物並びに腫瘍を治療する方法

Also Published As

Publication number Publication date
AU2018210748B2 (en) 2023-09-28
RU2019125724A (ru) 2021-02-19
SG10202107836SA (en) 2021-08-30
MX2019008533A (es) 2019-12-02
JP7232530B2 (ja) 2023-03-03
BR112019014718A2 (pt) 2020-03-10
TWI816656B (zh) 2023-10-01
RU2765736C2 (ru) 2022-02-02
JP2023002702A (ja) 2023-01-10
PH12019501650A1 (en) 2020-02-24
JP2020505451A (ja) 2020-02-20
IL268099B1 (en) 2024-01-01
WO2018136002A1 (en) 2018-07-26
EP3570818A4 (en) 2020-11-18
CN110381922A (zh) 2019-10-25
KR20190122676A (ko) 2019-10-30
EP3570818B1 (en) 2023-11-01
IL268099A (en) 2019-09-26
US20190358161A1 (en) 2019-11-28
IL268099B2 (en) 2024-05-01
EP3570818A1 (en) 2019-11-27
AU2018210748A1 (en) 2019-08-29
CL2019002002A1 (es) 2020-01-17
SG11201906539YA (en) 2019-08-27
TW201828925A (zh) 2018-08-16
US11331272B2 (en) 2022-05-17
RU2019125724A3 (es) 2021-03-04
CA3050686A1 (en) 2018-07-26
MA47319A (fr) 2019-11-27

Similar Documents

Publication Publication Date Title
CO2019008783A2 (es) Compuestos dinucleotidos ciclicos para el tratamiento del cancer
ECSP17073743A (es) Moduladores de k-ras
ECSP19070336A (es) Arn terapéutico
CL2020002914A1 (es) Métodos y composiciones para tratar el cáncer
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2018001230A1 (es) Tratamiento de osteoartritis
CL2018000429A1 (es) Moduladores de la expresión de kras
UY37464A (es) Métodos para tratar infecciones por el virus filoviridae
CY1122227T1 (el) Ρυθμιση δραστικοτητας συμπληρωματος
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
BR112018010464A8 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
CO2018002598A2 (es) Compuestos para modular la expresión de angiotensinógeno, composiciones que los contienen y procesos para su producción
EA201790737A1 (ru) Комбинированная терапия
EA202191009A1 (ru) Лечение b-клеточных злокачественных новообразований с применением комбинации ингибиторов jak и pi3k
PE20171094A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
EA201692473A1 (ru) Способы получения замещенных нуклеотидных аналогов
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
CO2017000950A2 (es) Compuestos que comprenden oligonucleótidos modificados dirigidos a mir-103 y/o mir-107 para trastornos metabólicos
CL2016001623A1 (es) Compuestos de benzamida y nicotinamida y métodos para usar los mismos.
BR112017022281A2 (pt) métodos para tratar câncer
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين